Immunologic and Therapeutic Synergy of IL-27 and IL-2: Enhancement of T Cell Sensitization, Tumor-Specific CTL Reactivity and Complete Regression of Disseminated Neuroblastoma Metastases in the Liver and Bone Marrow
Rosalba Salcedo(Frederick National Laboratory for Cancer Research), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Julie A. Hixon(Frederick National Laboratory for Cancer Research), Robert Kastelein(FX Palo Alto Laboratory), Alan D. Brooks(Science Applications International Corporation (United States)), George N. Pavlakis(National Institutes of Health), Barbara K. Felber(Frederick National Laboratory for Cancer Research), Tahira Khan(National Cancer Institute), Jimmy K. Stauffer(Frederick National Laboratory for Cancer Research), Giorgio Trinchieri(National Cancer Institute), Rashmi Jalah(Organogenesis (United States)), Ren‐Ming Dai, Douglas Powell(Data Management Services (United States)), Erin Lincoln(Science Applications International Corporation (United States)), Thomas J. Sayers(Science Applications International Corporation (United States)), Loretta Scheetz, Arthur A. Hurwitz(SUNY Upstate Medical University), Timothy Back(Science Applications International Corporation (United States))
Cited by 99
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k